The present invention relates to devices and methods for detecting the amount of material coating a medical device or substrate, in particular the present invention relates to devices and methods for detecting the amount of vaccine material coating a microarray patch.
Medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may be utilized to promote healing deliver drugs and provide pain relief Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. Medical devices that may be coated with various compounds include stents, grafts, anastomotic devices, perivascular wraps, sutures, staples and microprojection arrays. Microprojection arrays or micro array patches (MAPS) are an effective way of delivering therapeutic agents or biomarkers to patients as the patches induce minimal or no pain, induce little or no injury from the microneedles and reduce the possibility of cross infection. The solid projections or needles on a patch can be coated with drugs or macromolecules. These can be subsequently delivered to a desired target by the penetration of the projections or needles into the skin. The microprojections can be coated by the therapeutic agents using a variety of techniques such as dip coating, spray coating, gas jet drying, electrodynamic atomization and ink jet printing.
Regardless of the methods used for coating the microprojections on the arrays it is useful to assess the amount of material coating the target delivery region of the microprojections which is often the upper ½ to ¼ of the microprojections. Several different techniques have been applied in an attempt to quantify the amount of material coated onto the microprojections. One technique provides for dissolving the coating and quantifying the active material by high-performance liquid chromatography (Ma, et al. J. Pharm Sci. 2014 103(11): 3621-3630. Other techniques to determine the loading of material onto microprojection arrays include determining the residual amount of material either on the microprojections after use or on the skin after the microprojection array has been removed. Fluorescence microscopy can detect fluorescent materials on the microprojections or in the skin after the microprojection array has been removed. Scanning electron microscopy can be used to take images of the microprojections before and after coating. These techniques usually require destruction of the coating and/or are cumbersome and slow. There exists a need to assess each microprojection array at high speed in an aseptic manufacturing environment to determine that the dose and position of the coated material, such as a vaccine, on the projections is correct. Preferably, the method for assessing the dose and position of the coated material would not destroy the coating in the process.
As the dried vaccine on the microprojections appears optically “clear”, the use of standard imaging techniques to establish contrast between the coating and the polymer is not straightforward. Furthermore, it is desirable to determine if the upper portions of the microprojections are coated as this is the portion of the microprojection that enters the skin to deliver the material to the subject. Coating of the lower portions of the microprojections and/or the base upon which the microprojections rest is a waste of valuable biological material. The determination of the loading of the coating should be performed in an aseptic, non-destructive and rapid fashion.
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that the prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavor to which this specification relates.
The present invention relates to devices and methods for detecting the amount of material coating a medical device or substrate. In particular, the devices and methods of the present invention are able to detect the amount of vaccine material coating a microarray patch. Uncoated substrate surfaces (e.g. polymers) may have different reflectance and/or a fluorescence emission spectrum from a coated substrate when the substrate is irradiated with a radiation source. Often, the reflectance or fluorescence signal is reduced when the substrate is coated versus the uncoated substrate.
The devices and methods of the present invention enable the use of electromagnetic radiation directed onto an uncoated/coated microprojection array or micro array patch (MAP) to be reflected off the array or to induce an electromagnetic emission and detected to determine the extent of coating of the microprojections on the microprojection arrays. The use of a laser (or other illumination source with appropriate illumination filters), and an intensity sensor (with appropriately chosen collection filters) to measure the reflected or emitted intensity of the electromagnetic radiation from a coated MAP correlates with coating performance or transfer efficiency of the coating onto the microprojections.
Inkjet coating is an emerging technology that can aseptically coat biologics onto MAP's. High speed reflectance measurement(s) allows a quantifiable value to ascertain whether the coating on the projection meets specification in terms of the mass of coated material and its position on the patch relative to base.
In one broad form, an aspect of the present invention seeks to provide a method for determining the amount (degree, extent) of coating on microprojections of a coated microprojection array, the method comprising: irradiating an uncoated microprojection array with an electromagnetic radiation source; measuring the reflected radiation from the uncoated microprojection array; irradiating an uncoated microprojection array with an electromagnetic radiation source; measuring the reflected radiation from the uncoated microprojection array; and determining the extent of coating on the microprojections by comparing the reflected radiation from the uncoated microprojection array to that of the coated microprojection array.
In one embodiment, the measuring of the reflected radiation from the uncoated microprojection array and the measuring of the reflected radiation from the coated microprojection array is done simultaneously.
In one embodiment, the measuring of the reflected radiation from the uncoated microprojection array and the measuring of the reflected radiation from the coated microprojection array is done sequentially.
In another broad form, an aspect of the present invention seeks to provide a method for determining the amount of coating on the microprojections of a coated microprojection array, the microprojection array comprising a base from which the microprojections project, the method comprising: irradiating the coated microprojection array with a light source; measuring the reflected radiation from the base of the coated microprojection array; and determining the amount of coating on the microprojections by comparing the reflected radiation from the coated microprojection array to that of an uncoated microprojection array.
In one embodiment, the reflected radiation is measured by a sensor.
In one embodiment, the number of sensors is four.
In one embodiment, the sensors are at approximately 45 degree downward angle to the microprojections and at 45 degrees out of alignment with the rows of microprojections.
In one embodiment, the electromagnetic radiation source is substantially perpendicular to the microprojection array.
In one embodiment, the electromagnetic radiation source is at an angle relative to the microprojection array.
In one embodiment, the electromagnetic radiation source is aligned over the microprojection array such that the angle relative to the microprojections is less than 5°.
In one embodiment, the electromagnetic radiation source is aligned over the microprojection array such that the angle relative to the microprojections is less than about 20°.
In one embodiment, the electromagnetic radiation source is aligned over the microprojection array such that the angle relative to the microprojections is less than about 45°.
In another broad form, an aspect of the present invention seeks to provide a device for measuring the coating on the microprojections on a microprojection array, the device comprising: an electromagnetic radiation source for illuminating the microprojection array; a microprojection array housing for mounting the microprojection array; and one or more sensors for detecting reflected radiation from the microprojection array.
In one embodiment, the radiation source is a laser diode.
In one embodiment, the radiation source is a laser diode which emits radiation from about 200 nm to 10000 nm.
In one embodiment, the radiation source is a laser diode which emits radiation at 635 nm.
In one embodiment, the sensor is a silicon photodiode.
In one embodiment, the silicon photodiode has a detection range of 200 to 1100 nm.
In one embodiment, the device is confined in an aseptic housing.
In one embodiment, the device further comprises a reference sensor.
In one embodiment, the number of sensors is four.
In one embodiment, the sensors are at approximately 45 degree downward angle to the microprojections and at 45 degrees out of alignment with the rows of microprojections.
In one embodiment, the electromagnetic radiation source is substantially perpendicular to the microprojection array.
In one embodiment, the electromagnetic radiation source is aligned over the microprojection array such that the angle relative to the microprojections is less than 5°.
In another broad form, an aspect of the present invention seeks to provide a device for measuring the coating on the microprojections on a microprojection array, the device comprising: a laser diode for illuminating the microprojection array; an aspheric lens; abeam shaping diffuser; a focusing lens wherein the aspheric lens is positioned between the laser diode and the beam shaping diffuser and the beam shaping diffuser is positioned between the aspheric lens and the focusing lens and the focusing lens is positioned between the beam shaping filter and the microprojection array housing; microprojection array housing for mounting a microprojection array; a bi-convex lens; a sensor for detecting reflected light from the microprojection array wherein the biconvex lens is positioned between the microprojection array housing and the receiver; and a power meter connected to the sensor.
In one embodiment, the device further comprises a microarray mounting station.
In one embodiment, the device further comprises one or more microarrays.
In one embodiment, the laser diode emits electromagnetic radiation at bout 635 nm.
In one embodiment, the device further comprises an aperture positioned between the focusing lens and the microprojection array housing.
In one embodiment, the device further comprises a mirror positioned between the aperture and the microprojection array housing
In one embodiment, the device further comprises a reference sensor.
In one embodiment, the number of sensors is four.
In one embodiment, the sensors are at approximately 45 degree downward angle to the microprojections and at 45 degrees out of alignment with the rows of microprojections.
In one embodiment, the laser diode is substantially perpendicular to the microprojection array.
In one embodiment, the laser diode is aligned over the microprojection array such that the angle relative to the microprojections is less than 5°.
In another broad form, an aspect of the present invention seeks to provide a method for determining the extent (degree, amount) of coating on microprojections of a coated microprojection array comprising: irradiating an uncoated microprojection array with an electromagnetic radiation source; measuring the emitted radiation from the uncoated microprojection array; irradiating a coated microprojection array with a light source; measuring the emitted radiation from the coated microprojection array; and determining the extent of coating on the microprojections by comparing the emitted radiation from the uncoated microprojection array to that of the coated microprojection array.
In one embodiment, the emitted radiation is fluorescence.
In one embodiment, the electromagnetic radiation source emits at approximately 445 nm.
In one embodiment, the fluorescence is detected by a sensor with a filter having a bandpass of between about 455 nm to 515 nm.
In another broad form, an aspect of the present invention seeks to provide a method for determining the extent (degree, amount) of coating on a substrate comprising: irradiating an uncoated microprojection array with a first electromagnetic radiation source which reflects off the substrate and a second electromagnetic radiation source which promotes fluorescence in either the substrate or the coating or both; measuring the reflected radiation from the uncoated microprojection array; measuring the emitted fluorescence radiation from the uncoated microprojection array; irradiating a coated microprojection array with a first electromagnetic radiation source which reflects off the substrate and a second electromagnetic radiation source which promotes fluorescence in either the substrate or the coating or both irradiating a coated microprojection array with a light source; measuring the reflected radiation from the coated microprojection array; measuring the emitted fluorescence radiation from the coated microprojection array; and determining the extent of coating on the microprojections by comparing the reflected radiation from the uncoated microprojection array to that of the coated microprojection array and by comparing the reflected radiation from the uncoated microprojection array to that of the coated microprojection array.
In another broad form, an aspect of the present invention seeks to provide a method for controlling the quality of coated microprojection arrays, the method including: determining the amount (degree, extent) of coating on microprojections of a coated microprojection array using the method as described above; comparing the determined amount of coating to a coating specification; and rejecting the coated microprojection array if the determined amount of coating is outside of the coating specification.
In another broad form, an aspect of the present invention seeks to provide a system for controlling the quality of coated microprojection arrays, the system including a device as described above that determines the amount of coating on microprojections of a coated microprojection array; and a processing system configured to: receive, from the device, an indication of the determined amount of coating; compare the determined amount of coating to a coating specification; and determine that the coated microprojection array should be rejected if the determined amount of coating is outside of the coating specification.
It will be appreciated that the broad forms of the invention and their respective features can be used in conjunction, interchangeably and/or independently, and reference to separate broad forms is not intended to be limiting.
Various examples and embodiments of the present invention will now be described with reference to the accompanying drawings, in which:—
The present invention relates to devices and methods for detecting the amount of material coating a medical device or substrate, in particular the present invention relates to devices and methods for detecting the amount of vaccine material coating a microarray patch in real time.
The patches take a variety of forms from metal formed patches to polymer molded patches to patch projections formed from the vaccine or pharmacological solution itself. The manufacture of these patches relies on the ability to deposit a dried down drug solution or vaccine onto the tips of the microprojections with high throughput and high accuracy. Accurately coating the projections is important as the delivery of the coated material to the patient needs to be consistent. If too little material is delivered the efficacy of the treatment is compromised. Too much material could lead to overdosing or at a minimum wasting expensive vaccine or drug. The ability to coat the patches quickly is necessary to producing a commercial product. Coating of a Micro Array Patch (MAP) and other vaccine and biologic platforms requires the precise dosing and allocation of biologics targeting each individual projection on the platform with a controlled dose. Typically, a MAP (Micro Array Patch) platform has a length and a width of less than 20 mm and carries an evenly spaced two-dimensional array of projections. The microprojections are situated on a substantially planar base. The number of projections in either dimension may be less than 100. Therefore the projection density on the MAP is usually between 2,000 and 10,000 per cm2. The total amount of pharmaceutical formulation such as a vaccine required to coat each projection is typically more than 500 picolitres and must be accurately measured both in terms of the applied dried volume of material and the position of the material on the microprojection. For example it would be informative to determine whether the material deposited on the microprojections was located on the top fourth of the microprojection or top half of the microprojection or whether the entire microprojection was coated. Furthermore, in order to accomplish large volume manufacturing of MAPs, each patch may need to be coated with one or more drops (e.g. 1-6 drops per microprojection or between 20 pl to 1 μL of material) in in a short time period (e.g. seconds). It is important to be able to quantify the amount of material that is distributed onto the microprojections in a manner that is preferably non-destructive and which does not contact the material or the microprojections. The method should be rapid enough to keep up with production levels of microprojection arrays which could number in the millions per week. The devices and methods of the present invention provide the ability to determine the amount of material coated onto the microprojections of the MAP.
The devices and methods of the present invention can determine the amount of material deposited on a substrate where the substrate is made of both an area that is nominally “to be coated” and an area that is nominally “uncoated”. The measurement of the coating distribution can in principle be made by the direct measurement of the material on the coated area of the substrate or inferred by the measurement of the absence of material in the nominally uncoated area of the substrate. For example with respect to microprojection arrays which are made of abase from which microprojections arise, the coated area is the tips of the microprojections (preferably the top half of the microprojections) and the uncoated area is the base from which the microprojections arise (preferably the lower 50% of the projection). Thus the measurement of the material on the microprojections can be made either directly by determining the amount of material on the microprojections or by the measurement of material on the base from which the amount of material on the microprojections can be determined. The devices and methods of the present invention enable the use of electromagnetic radiation directed onto an uncoated/coated microprojection array or micro array patch (MAP) to be reflected off the array or to induce an electromagnetic emission and detected to determine the extent of coating of the microprojections on the microprojection arrays. In the devices and methods of the present invention the detection of the coating on the MAP may utilize one or more electromagnetic radiation wavelengths for reflectance measurements or fluorescence detection. The devices and methods of the present invention may use reflectance measurements and fluorescence measurements alone or in combination either simultaneously or sequentially. Optics may be required for reflectance mode measurements to make sure illumination is collimated. Fluorescence mode illumination may not require collimated light.
The use of a laser (or other illumination source with appropriate illumination filters), and an intensity sensor (with appropriately chosen collection filters) to measure the reflected or emitted intensity of the electromagnetic radiation from a coated MAP correlates with coating performance or transfer efficiency of the coating onto the microprojections. The sensor may ideally have optics for both reflectance and fluorescence mode measurements in order to maximize signal collection and directionality of photons.
In the devices and the methods of the present invention the uncoated surfaces of the MAP (e.g. a polymer microprojection array patch) have different reflectance and/or fluorescence emission spectra from a polymer surface that is coated; the orientation of the sensor relative to the substrate surface being measured can assist in isolating signals that are primarily related to coating on either the base region, or the tip region (depending on the sensor configuration); coating on a surface is detected as a reduction in the signal intensity compared to the signal from a reference surface; the reference surface can be an uncoated patch or a measurement made at a wavelength where the coating is substantially transparent, and is thus representative of an uncoated patch. For example, in a reflectance configuration for measuring a signal related to the amount of base coating the illumination source and sensor may be positioned such that if the patch were replaced by a mirror, the beam would reflect off the mirror and enter directly in alignment with the sensor optics detection path. When the mirror is replaced with a microprojection patch, the illumination will, like the mirror, substantially reflect off of the base region of the patch. Regions of the patch, where there are microprojections, will not contribute a significant signal in the direction of the sensor since the microprojections are substantially orthogonal to the base of the patch. Therefore, the measured signal is primarily from the reflection of the electromagnetic radiation from the base. However, if a material such as a vaccine is present on the base, the material will act to reduce the reflected signal (either from absorption by the material or by scattering). If the quantity of material deposited onto the patch is known and controlled, the amount of coating on the tips can then be inferred from the measured quantity on the base. In the case where material is substantially deposited on the tips with little material deposited on the base, the measured reflectance intensity signal will be high (ostensibly the same or similar as an uncoated patch). If material is instead deposited on the base, the reflected intensity will be reduced. Thus, if a high proportion of tip is coated the result will be the detector will observe a large signal, whereas a low proportion of tip coating will result in a small signal.
In one embodiment of the devices of the present invention the device is comprised of a radiation (light) source, a coated microprojection array and a sensor for detecting radiation (light). The radiation source illuminates the coated array and the sensor is positioned such that it can detect the radiation reflected from the coated array. To determine the amount of coating on the microprojection array the value of reflected light derived from the sensor may be compared to the value of reflected light derived from the sensor when the same radiation source is reflected off an uncoated microprojection array. A normalized reflectance diagram can be constructed (See
As described above the reflectance from the coated patch may be compared to the reflectance from the uncoated patch. This comparison could be accomplished by having an uncoated and coated patch illuminated simultaneously or sequentially. The comparison could also be accomplished by comparing a portion of a single patch which contains both coated and uncoated sections.
In addition to the basic scheme described above other optical equipment and/or mechanical equipment may also be included in the devices and methods of the present invention. Various lenses, filters and mirrors to optimize the illumination of the patch as well as providing optimal conditions for detection of the reflected light may be provided. A housing that provides aseptic or sterile conditions for the microarray can also be part of the devices of the present invention. It is desirable to maintain an aseptic or sterile environment so that the microarrays are not contaminated as the coatings on the microprojections are to be inserted into patients.
In the devices and methods of the present invention various radiation sources may be used including but not limited to laser sources, infrared sources and fluorescence sources. In some embodiments of the devices and methods of the present invention the wavelength of the radiation source may be at a wavelength or wavelengths at which the coating strongly absorbs. In other embodiments, the dried coating material may either strongly emit fluorescence in response to the excitation wavelength, or strongly absorb or scatter at the emitted fluorescence wavelength of the underlying polymer substrate. The direction of the illumination source and the detector patch may influence the quality and information received, especially for detection based on reflectance, the orientation of the sensor relative to the microprojection array surface being measured can assist in isolating signals that are primarily related to coating on either the base region, or the tip region (depending on the sensor configuration). Illuminating near normal to patch surface results in a signal that is almost entirely due to the base reflectance (reflections from projections do not return to the sensor). Reflectance is reduced when coating is present, due to either absorbance by the coating, or scattering from the dried solids deposits. Placing the sensor at an angle such that tips of other projections in the array mask or shadow the base portion of the projections as well as the base of the patch coating on a surface is detected as a reduction (or increase in some cases) in the signal intensity compared to the signal from a reference surface. Illumination should be electromagnetic radiation source with a defined wavelength (or wavelengths if 2 or more are needed)
The orientation of the electromagnetic radiation source and the sensors influence the reflectance signal that registers with the detectors. For example, if the detector and illumination source are oriented as in
The size of the area illuminating the substrate, such as a microprojection array will also influence the quality of the data. For example if the area of illumination is a large area relative to the entirety of the substrate the information gathered from the reflectance data will relate to an average coating over the entire substrate. Smaller areas of illumination relative to the entirety of the substrate will provide more data about the coating of particular areas of the substrate. The smaller the area of illumination the greater the detail of the coating on the substrate. For example more detail will be gained by illuminating a single microprojection than illuminating the entire microprojection array.
Alternatively the use of fluorescence rather than reflectance may decrease the dependence of the signal on the geometry of the radiation source and the detectors as fluorescence emits in all directions. In the case of reflectance the signal may be reduced by as much as 95% if the source of the radiation is normal to the patch. Conversely, if the source of radiation is normal to the patch when using fluorescence detection, the signal is only marginally reduced. If a coating is coated onto a substrate such as on the microprojections of a microprojection array the wavelength for excitation and the wavelength range for an emission filter can provide scenarios where the coating such as a vaccine may either mask the fluorescence of the patch (polymer) or provide little or no masking of the fluorescence of the patch (polymer). For example, in
The use of Fourier Transform Infrared Spectroscopy (FTIR) may be used to assist in identifying optimal wavelengths for detection of the coating on a substrate. To achieve maximum sensitivity, it may be desirable to select a wavelength where the dried vaccine absorbs strongly compared to the polymer (See
The sensor can be a detector such as a photodiode including but not limited to silicon photodiodes preferably with a wavelength range 400-1100 nm, power range 500 pW-500 mW and coated with an ND reflective coating. Placing a filter in front of the sensor can be used to reduce stray signals from light coming from the production environment. A filter can filter out the excitation wavelength when a fluorescence signal is being measured. Additionally, optical elements placed in front of the sensor may assist is maximizing the specificity in directionality and signal amplitude. The sensor can be directly read by a power meter console which is compatible with the receiver or a PLC system which reads the power sensor measurements, processes them, and feeds the information into the production system.
Optionally a reference sensor as shown in
In one embodiment the signals from the sensor are normalized by measuring a blank (uncoated) patch prior to or simultaneously with measuring the signal for coated patches. The ratio of the coated patch signal to the uncoated patch signal may then be calculated.
As shown in
It is also possible to illuminate at an angle such that using the geometry of the patch a shadow could be cast on the lower part of the projection and leave a signal that is primarily from the tips of the microprojections rather than from the base.
In alternative embodiments of the present invention a “spectral” measurement may be taken in which multiple wavelengths are monitored for intensity spectra which may be signatures of different components in the coating or the polymer patch.
As described above, the instruments, devices and methods of the present invention need to provide high throughput quality solutions for determining the coating on the microprojection arrays. This includes having the patches that will be coated in a format where they can be coated, checked for quality and transported easily. A method for providing patches that can be coated by commercial production is to interconnect the individual MAP's into compact mats that can be further stacked into a single compact body that requires minimal packaging (
The sequence begins with the system start up for each print head in which a start priming sequence is initiated to expel air from the print circuit. Once primed, printer will idle (tickle). The print head will print a single dispense onto a hydrophobic surface, image system counts drops, measures drop diameter and aligns print head to X, Y, axis and rotation. Drop size can be adjusted via PZT voltage.
Next an array of patches (Mat) is aligned under the print head, each patch is imaged and the position of the patch relative to axis is determined. Print head vision systems (P1 to P4) inspect patches and mark rejects (missing projections, no tips or damage). In addition periodic checks of drop mass dispense can be performed to confirm target dispense. The voltage supplied to PZT may be altered to achieve the mean dispensing value. Printing can then commence and a coating is built up on the microprojections by multiple passes depending on required dose. The printed mat of patches is then transferred to coating QC conveyor.
The mat patch passes under QC station and reflected light of various wavelengths may be used to collect data per patch. Such data may include where the coating is positioned on projection and estimates of the dispensed mass per patch. Mass may be calculated by reading fluorescence emitted from one component of a homogeneous coating material or the patch itself. This data from the fluorescence scan may be checked against the dispensed mass check for that print head to confirm the any deviations from the established protocol. Any out of specification patches are rejected at the patch insertion stage.
In view of the above, it will be appreciated that a method for controlling the quality of coated microprojection arrays may include determining the amount of coating on microprojections of a coated microprojection array using the above described techniques, comparing the determined amount of coating to a coating specification; and rejecting the coated microprojection array if the determined amount of coating is outside of the coating specification.
Similarly, it will be appreciated that a system for controlling the quality of coated microprojection arrays may include a device that determines the amount of coating on microprojections of a coated microprojection array as described above, together with a processing system configured to receive from the device an indication of the determined amount of coating, compare the determined amount of coating to a coating specification and determine that the coated microprojection array should be rejected if the determined amount of coating is outside of the coating specification.
Within this disclosure, any indication that a feature is optional is intended provide adequate support (e.g., under 35 U.S.C. 112 or Art. 83 and 84 of EPC) for claims that include closed or exclusive or negative language with reference to the optional feature. Exclusive language specifically excludes the particular recited feature from including any additional subject matter. For example, if it is indicated that A can be drug X, such language is intended to provide support for a claim that explicitly specifies that A consists of X alone, or that A does not include any other drugs besides X. “Negative” language explicitly excludes the optional feature itself from the scope of the claims. For example, if it is indicated that element A can include X, such language is intended to provide support for a claim that explicitly specifies that A does not include X. Non-limiting examples of exclusive or negative terms include “only,” “solely,” “consisting of,” “consisting essentially of,” “alone,” “without”, “in the absence of (e.g., other items of the same type, structure and/or function)” “excluding,” “not including”, “not”, “cannot,” or any combination and/or variation of such language.
Similarly, referents such as “a,” “an,” “said,” or “the,” are intended to support both single and/or plural occurrences unless the context indicates otherwise. For example “a dog” is intended to include support for one dog, no more than one dog, at least one dog, a plurality of dogs, etc. Non-limiting examples of qualifying terms that indicate singularity include “a single”, “one,” “alone”, “only one,” “not more than one”, etc. Non-limiting examples of qualifying terms that indicate (potential or actual) plurality include “at least one,” “one or more,” “more than one,” “two or more,” “a multiplicity,” “a plurality,” “any combination of,” “any permutation of,” “any one or more of,” etc. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context.
Where ranges are given herein, the endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
Throughout this specification and claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or group of integers or steps but not the exclusion of any other integer or group of integers. As used herein and unless otherwise stated, the term “approximately” means±20%.
While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that the various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
A better understanding of the present invention and of its many advantages will be had from the following examples, given by way of illustration.
Normalized Reflectance
A range of coating performance was obtained by creating three different groups of microprojection patch arrays. Each patch was coated with 6 drops of 14C labelled vaccine per projection. The three groups were then manufactured as follows: In group I six drops were targeted to the tips of the microprojections; in group II, three drops were targeted to tips of the microprojections and three drops targeted to the base; and in group III, six drops were targeted to the base and no drops targeted to the micro projections. Multiple replicates of each group were manufactured. As the process for targeting the drops to particular portions of the array cannot as yet be perfectly replicated there was a spread of coating performance instead of simply three clusters at 0%, 50% and 100% coating. These microprojection arrays were made in duplicate (TN821 and TN 848). Both sets of microarrays were subjected to reflectance measurements as were microarrays which were uncoated.
The quantitation of the coating for a first set (TN 821) of microarrays was measured by a membrane transfer method where a porous 100 micron thick membrane is used to remove the coated material from the top 100 microns of the projections. The membrane (PVDF with 0.4 micron pores) was hydrated with ¼ strength phosphate buffer and placed against a rigid surface (e.g. glass slides). The patch was placed with the projection side facing the membrane and a pneumatic press was used to press the projections into the membrane for 5 seconds at 40 PSI. Projections penetrate the membrane and stop when the microprojection tips reach the glass surface. Thus, the thickness of the membrane and the pressure (to some extent) control the penetration of the microprojections into the membrane. The coating transfers to the membrane where it was retained due to the hydrophobic interactions between the coating and the membrane. The membrane is hydrated and is a high protein binding membrane traditionally used in blotting techniques for protein analysis. The remaining material (that was not transferred to the membrane) was eluted from the patch and the material bound to the membrane was quantified by using scintillation counting.
The results of the reflectance studies are show in
Large Spot Reflectance
Eight MAPs were coated respectively with the following coatings: 30%, 60%, 80% and 100% high dose coating and 30%, 60%, 80% and 100% low dose coating. A laser source illuminated a 7 mm spot on the microprojection array and reflectance was measured. The amount of coating was plotted versus reflectance as seen in
Spatially Resolved QC Measurements
A single MAP was coated with 4 different tip targeting accuracies as shown in
Number | Name | Date | Kind |
---|---|---|---|
2213830 | Anastasi | Sep 1940 | A |
2881500 | Furness | Apr 1959 | A |
4702799 | Tuot | Oct 1987 | A |
5017007 | Milne et al. | May 1991 | A |
5201992 | Andreadakis et al. | Apr 1993 | A |
5353792 | Lubbers et al. | Oct 1994 | A |
5449064 | Hogan et al. | Sep 1995 | A |
5457041 | Ginaven et al. | Oct 1995 | A |
5461482 | Wilson et al. | Oct 1995 | A |
5499474 | Knooihuizen | Mar 1996 | A |
5527288 | Gross et al. | Jun 1996 | A |
5611806 | Jang | Mar 1997 | A |
5657138 | Lewis et al. | Aug 1997 | A |
5859937 | Nomura | Jan 1999 | A |
5870806 | Black, Jr. | Feb 1999 | A |
5922356 | Koseki et al. | Jul 1999 | A |
5928207 | Pisano et al. | Jul 1999 | A |
5943075 | Lee et al. | Aug 1999 | A |
6052652 | Lee | Apr 2000 | A |
6233797 | Neely et al. | May 2001 | B1 |
6287556 | Portnoy et al. | Sep 2001 | B1 |
6299621 | Fogarty et al. | Oct 2001 | B1 |
6334856 | Allen et al. | Jan 2002 | B1 |
6352697 | Cox et al. | Mar 2002 | B1 |
6454755 | Godshall | Sep 2002 | B1 |
6463312 | Bergveld et al. | Oct 2002 | B1 |
6478738 | Hirabayashi et al. | Nov 2002 | B1 |
6503231 | Prausnitz et al. | Jan 2003 | B1 |
6533949 | Yeshurun et al. | Mar 2003 | B1 |
6537242 | Palmer | Mar 2003 | B1 |
6537264 | Cormier et al. | Mar 2003 | B1 |
6551849 | Kenney | Apr 2003 | B1 |
6557849 | Wyss | May 2003 | B2 |
6558361 | Yeshurun | May 2003 | B1 |
6565532 | Yuzhakov et al. | May 2003 | B1 |
6589202 | Powell | Jul 2003 | B1 |
6591124 | Sherman et al. | Jul 2003 | B2 |
6610382 | Kobe et al. | Aug 2003 | B1 |
6743211 | Prausnitz et al. | Jun 2004 | B1 |
6749575 | Matriano et al. | Jun 2004 | B2 |
6855372 | Trautman et al. | Feb 2005 | B2 |
6881203 | Delmore et al. | Apr 2005 | B2 |
6908453 | Fleming et al. | Jun 2005 | B2 |
6923764 | Aceti et al. | Aug 2005 | B2 |
6931277 | Yuzhakov et al. | Aug 2005 | B1 |
6945952 | Kwon | Sep 2005 | B2 |
7022071 | Schaupp et al. | Apr 2006 | B2 |
7045069 | Ozeryansky | May 2006 | B2 |
7048723 | Frazier et al. | May 2006 | B1 |
7097631 | Trautman et al. | Aug 2006 | B2 |
7169600 | Hoss et al. | Jan 2007 | B2 |
7211062 | Kwon | May 2007 | B2 |
7250037 | Shermer et al. | Jul 2007 | B2 |
7316665 | Laurent et al. | Jan 2008 | B2 |
7753888 | Mukerjee et al. | Jul 2010 | B2 |
8052633 | Kendall | Nov 2011 | B2 |
8062573 | Kwon | Nov 2011 | B2 |
8267889 | Cantor et al. | Sep 2012 | B2 |
8414548 | Yuzhakov | Apr 2013 | B2 |
8540672 | McAllister | Sep 2013 | B2 |
8734697 | Chen et al. | May 2014 | B2 |
8883015 | Kendall et al. | Nov 2014 | B2 |
9199976 | Smythe et al. | Dec 2015 | B2 |
9220678 | Kendall et al. | Dec 2015 | B2 |
9283365 | Kendall et al. | Mar 2016 | B2 |
9387000 | Corrie et al. | Jul 2016 | B2 |
9572969 | Kendall | Feb 2017 | B2 |
9888932 | Kendall | Feb 2018 | B2 |
9943673 | Kendall et al. | Apr 2018 | B2 |
10022322 | Kendall et al. | Jul 2018 | B2 |
10751072 | Kendall | Aug 2020 | B2 |
11103259 | Crichton et al. | Aug 2021 | B2 |
11147954 | Junger et al. | Oct 2021 | B2 |
11179553 | Kendall et al. | Nov 2021 | B2 |
11207086 | Kendall | Dec 2021 | B2 |
20020008530 | Kim et al. | Jan 2002 | A1 |
20020016562 | Cormier et al. | Feb 2002 | A1 |
20020032415 | Trautman et al. | Mar 2002 | A1 |
20020128599 | Cormier et al. | Sep 2002 | A1 |
20020133129 | Arias et al. | Sep 2002 | A1 |
20020169411 | Sherman et al. | Nov 2002 | A1 |
20020177839 | Cormier et al. | Nov 2002 | A1 |
20030036710 | Matriano et al. | Feb 2003 | A1 |
20030090558 | Coyle et al. | May 2003 | A1 |
20030199810 | Trautman et al. | Oct 2003 | A1 |
20030199811 | Sage et al. | Oct 2003 | A1 |
20030202050 | Mrvos et al. | Oct 2003 | A1 |
20030220656 | Gartstein et al. | Nov 2003 | A1 |
20040002121 | Regan et al. | Jan 2004 | A1 |
20040004649 | Bibl et al. | Jan 2004 | A1 |
20040008241 | Junhua | Jan 2004 | A1 |
20040039397 | Weber et al. | Feb 2004 | A1 |
20040049150 | Dalton et al. | Mar 2004 | A1 |
20040087992 | Gartstein et al. | May 2004 | A1 |
20040161470 | Andrianov et al. | Aug 2004 | A1 |
20050042866 | Klapproth et al. | Feb 2005 | A1 |
20050089553 | Cormier et al. | Apr 2005 | A1 |
20050089554 | Cormier et al. | Apr 2005 | A1 |
20050126710 | Laermer et al. | Jun 2005 | A1 |
20050137531 | Prausnitz et al. | Jun 2005 | A1 |
20050143713 | Delmore et al. | Jun 2005 | A1 |
20050197308 | Dalton et al. | Sep 2005 | A1 |
20050261632 | Xu | Nov 2005 | A1 |
20060012780 | Nishiyama et al. | Jan 2006 | A1 |
20060015061 | Kuo et al. | Jan 2006 | A1 |
20060055724 | Krawczyk et al. | Mar 2006 | A1 |
20060074376 | Kwon | Apr 2006 | A1 |
20060195125 | Sakakine et al. | Aug 2006 | A1 |
20060202385 | Xu et al. | Sep 2006 | A1 |
20060264782 | Holmes et al. | Nov 2006 | A1 |
20070027474 | Lasner | Feb 2007 | A1 |
20070060867 | Xu | Mar 2007 | A1 |
20070078376 | Smith | Apr 2007 | A1 |
20070224252 | Trautman et al. | Sep 2007 | A1 |
20070264749 | Birkmeyer | Nov 2007 | A1 |
20070270738 | Wu et al. | Nov 2007 | A1 |
20070293815 | Chan et al. | Dec 2007 | A1 |
20070299388 | Chan et al. | Dec 2007 | A1 |
20080009811 | Cantor | Jan 2008 | A1 |
20080108959 | Jung et al. | May 2008 | A1 |
20080114298 | Cantor et al. | May 2008 | A1 |
20080136874 | Tsukamura | Jun 2008 | A1 |
20080183144 | Trautman et al. | Jul 2008 | A1 |
20080245764 | Pirk et al. | Oct 2008 | A1 |
20080287858 | Duan | Nov 2008 | A1 |
20080312610 | Binks et al. | Dec 2008 | A1 |
20080312669 | Vries et al. | Dec 2008 | A1 |
20090017210 | Andrianov et al. | Jan 2009 | A1 |
20090041810 | Andrianov et al. | Feb 2009 | A1 |
20090198189 | Simons et al. | Aug 2009 | A1 |
20090292254 | Tomono | Nov 2009 | A1 |
20100156998 | Matsumoto et al. | Jun 2010 | A1 |
20100221314 | Matsudo et al. | Sep 2010 | A1 |
20100222743 | Frederickson et al. | Sep 2010 | A1 |
20100256568 | Frederickson et al. | Oct 2010 | A1 |
20100271305 | Chen | Oct 2010 | A1 |
20100302322 | Wang | Dec 2010 | A1 |
20110021996 | Lee et al. | Jan 2011 | A1 |
20110028905 | Takada | Feb 2011 | A1 |
20110059150 | Kendall et al. | Mar 2011 | A1 |
20110160069 | Corrie et al. | Jun 2011 | A1 |
20110223542 | Kendall | Sep 2011 | A1 |
20110245776 | Kendall | Oct 2011 | A1 |
20110276027 | Trautman et al. | Nov 2011 | A1 |
20110288484 | Kendall et al. | Nov 2011 | A1 |
20120004626 | Kuwahara et al. | Jan 2012 | A1 |
20120027810 | Chen et al. | Feb 2012 | A1 |
20120041412 | Roth et al. | Feb 2012 | A1 |
20120083741 | Kendall | Apr 2012 | A1 |
20120083762 | Kendall | Apr 2012 | A1 |
20120109065 | Backes | May 2012 | A1 |
20120136312 | Terahara et al. | May 2012 | A1 |
20120220981 | Soo et al. | Aug 2012 | A1 |
20120265141 | Kalpin et al. | Oct 2012 | A1 |
20120277629 | Bernstein et al. | Nov 2012 | A1 |
20120330250 | Kuwahara et al. | Dec 2012 | A1 |
20130079666 | Gonzalez-Zugasti et al. | Mar 2013 | A1 |
20130106964 | Rueby et al. | May 2013 | A1 |
20130131598 | Trautman et al. | May 2013 | A1 |
20130150822 | Ross | Jun 2013 | A1 |
20130158468 | Bernstein et al. | Jun 2013 | A1 |
20130158482 | Davis et al. | Jun 2013 | A1 |
20130190794 | Kendall et al. | Jul 2013 | A1 |
20130296790 | Masaoka et al. | Nov 2013 | A1 |
20130337150 | Biemans | Dec 2013 | A1 |
20140066842 | Zhang et al. | Mar 2014 | A1 |
20140243747 | Tokumoto et al. | Aug 2014 | A1 |
20140257188 | Kendall et al. | Sep 2014 | A1 |
20140276366 | Bourne et al. | Sep 2014 | A1 |
20140276378 | Chen et al. | Sep 2014 | A1 |
20140276474 | Ding et al. | Sep 2014 | A1 |
20150057604 | Arami et al. | Feb 2015 | A1 |
20150080844 | Donovan et al. | Mar 2015 | A1 |
20160015952 | Omachi et al. | Jan 2016 | A1 |
20160058697 | Kendall et al. | Mar 2016 | A1 |
20160220803 | Kendall et al. | Aug 2016 | A1 |
20160271381 | Falo, Jr. et al. | Sep 2016 | A1 |
20160310412 | Tanque et al. | Oct 2016 | A1 |
20170014336 | Kuruma et al. | Jan 2017 | A1 |
20170056637 | Unger et al. | Mar 2017 | A1 |
20170057124 | Wakamatsu et al. | Mar 2017 | A1 |
20170065804 | Uemura | Mar 2017 | A1 |
20170182301 | Kendall | Jun 2017 | A1 |
20170189660 | Baek | Jul 2017 | A1 |
20170239458 | Kato et al. | Aug 2017 | A1 |
20170282417 | Okano et al. | Oct 2017 | A1 |
20170296465 | Yoshida et al. | Oct 2017 | A1 |
20170361082 | Okano et al. | Dec 2017 | A1 |
20170368322 | Kato et al. | Dec 2017 | A1 |
20180015271 | Junger et al. | Jan 2018 | A1 |
20180161050 | Kendall | Jun 2018 | A1 |
20180250503 | Enomoto et al. | Sep 2018 | A1 |
20180263641 | Crichton et al. | Sep 2018 | A1 |
20180264244 | Meliga et al. | Sep 2018 | A1 |
20180326726 | Wang et al. | Nov 2018 | A1 |
20190001109 | Kim et al. | Jan 2019 | A1 |
20190046479 | Pathak | Feb 2019 | A1 |
20200246450 | Junger et al. | Aug 2020 | A1 |
20200246545 | Langer et al. | Aug 2020 | A1 |
20200368511 | Lemaire | Nov 2020 | A1 |
20200405331 | Kendall | Dec 2020 | A1 |
20210170152 | Kendall et al. | Jun 2021 | A1 |
20210244926 | Meliga et al. | Aug 2021 | A1 |
20210270599 | Junger et al. | Sep 2021 | A1 |
Number | Date | Country |
---|---|---|
1149018 | May 1997 | CN |
101214395 | Jul 2008 | CN |
101297989 | Nov 2008 | CN |
104027324 | Sep 2014 | CN |
104706626 | Jun 2015 | CN |
0 139 286 | May 1985 | EP |
0139286 | May 1985 | EP |
0 732 208 | Sep 1996 | EP |
0732208 | Sep 1996 | EP |
1 695 734 | Jun 2008 | EP |
1695734 | Jun 2008 | EP |
2211089 | Jul 2010 | EP |
2211089 | Jul 2010 | EP |
2 213 284 | Aug 2010 | EP |
2213284 | Aug 2010 | EP |
2 327 419 | Jun 2011 | EP |
2327419 | Jun 2011 | EP |
2 568 174 | Mar 2013 | EP |
2568174 | Mar 2013 | EP |
2 835 147 | Feb 2015 | EP |
2835147 | Feb 2015 | EP |
3185179 | Jun 2017 | EP |
3185179 | Jun 2017 | EP |
2003-127430 | May 2003 | JP |
2003127430 | May 2003 | JP |
3543790 | Jul 2004 | JP |
2007260889 | Oct 2007 | JP |
2007-260889 | Nov 2007 | JP |
2008114561 | May 2008 | JP |
2009276382 | Nov 2009 | JP |
2010-071845 | Apr 2010 | JP |
2010071845 | Apr 2010 | JP |
2010071845 | Apr 2010 | JP |
2010091343 | Apr 2010 | JP |
2013043034 | Mar 2013 | JP |
2016-166769 | Sep 2016 | JP |
2016166769 | Sep 2016 | JP |
2017009514 | Jan 2017 | JP |
9106571 | May 1991 | WO |
9106571 | May 1991 | WO |
9424281 | Oct 1994 | WO |
9424281 | Oct 1994 | WO |
9828037 | Jul 1998 | WO |
9828038 | Jul 1998 | WO |
WO 9828037 | Jul 1998 | WO |
WO 9828038 | Jul 1998 | WO |
9902694 | Jan 1999 | WO |
WO 9902694 | Jan 1999 | WO |
9942564 | Aug 1999 | WO |
WO 9942564 | Aug 1999 | WO |
9964580 | Dec 1999 | WO |
WO 9964580 | Dec 1999 | WO |
0005339 | Feb 2000 | WO |
WO 0005339 | Feb 2000 | WO |
0042215 | Jul 2000 | WO |
WO 0042215 | Jul 2000 | WO |
WO 0044438 | Aug 2000 | WO |
0074763 | Dec 2000 | WO |
0074764 | Dec 2000 | WO |
WO 0074763 | Dec 2000 | WO |
WO 0074764 | Dec 2000 | WO |
0133614 | May 2001 | WO |
WO 0133614 | May 2001 | WO |
0185207 | Nov 2001 | WO |
WO 0185207 | Nov 2001 | WO |
02064193 | Aug 2002 | WO |
WO 02064193 | Aug 2002 | WO |
02074173 | Sep 2002 | WO |
02075794 | Sep 2002 | WO |
WO 02074173 | Sep 2002 | WO |
WO 02075794 | Sep 2002 | WO |
02085446 | Oct 2002 | WO |
02085447 | Oct 2002 | WO |
WO 02085446 | Oct 2002 | WO |
WO 02085447 | Oct 2002 | WO |
2002100476 | Dec 2002 | WO |
WO 02100476 | Dec 2002 | WO |
03020359 | Mar 2003 | WO |
WO 03020359 | Mar 2003 | WO |
03026732 | Apr 2003 | WO |
WO 03026732 | Apr 2003 | WO |
03048031 | Jun 2003 | WO |
WO 03048031 | Jun 2003 | WO |
03053258 | Jul 2003 | WO |
WO 03053258 | Jul 2003 | WO |
03078925 | Sep 2003 | WO |
WO 03078925 | Sep 2003 | WO |
03092785 | Nov 2003 | WO |
WO 03092785 | Nov 2003 | WO |
2004000389 | Dec 2003 | WO |
WO 2004000389 | Dec 2003 | WO |
2004024224 | Mar 2004 | WO |
WO 2004024224 | Mar 2004 | WO |
2005049108 | Jun 2005 | WO |
WO 2005049108 | Jun 2005 | WO |
2005060621 | Jul 2005 | WO |
WO 2005060621 | Jul 2005 | WO |
2005069736 | Aug 2005 | WO |
2005072630 | Aug 2005 | WO |
WO 2005069736 | Aug 2005 | WO |
2005123173 | Dec 2005 | WO |
WO 2005123173 | Dec 2005 | WO |
2006055795 | May 2006 | WO |
2006055799 | May 2006 | WO |
WO 2006055795 | May 2006 | WO |
WO 2006055799 | May 2006 | WO |
2006101459 | Sep 2006 | WO |
WO 2006101459 | Sep 2006 | WO |
2006108185 | Oct 2006 | WO |
WO 2006108185 | Oct 2006 | WO |
2006116281 | Nov 2006 | WO |
WO 2006116281 | Nov 2006 | WO |
2006138719 | Dec 2006 | WO |
WO 2006138719 | Dec 2006 | WO |
2007002123 | Jan 2007 | WO |
2007002521 | Jan 2007 | WO |
WO 2007002123 | Jan 2007 | WO |
WO 2007002521 | Jan 2007 | WO |
2007012114 | Feb 2007 | WO |
WO 2007012114 | Feb 2007 | WO |
2007030477 | Mar 2007 | WO |
WO 2007030477 | Mar 2007 | WO |
2007054090 | May 2007 | WO |
2007061781 | May 2007 | WO |
WO 2007054090 | May 2007 | WO |
WO 2007061781 | May 2007 | WO |
2007070004 | Jun 2007 | WO |
WO 2007070004 | Jun 2007 | WO |
2007080427 | Jul 2007 | WO |
WO 2007080427 | Jul 2007 | WO |
2007124411 | Nov 2007 | WO |
2007127976 | Nov 2007 | WO |
WO 2007124411 | Nov 2007 | WO |
WO 2007127976 | Nov 2007 | WO |
2008010681 | Jan 2008 | WO |
2008011625 | Jan 2008 | WO |
WO 2008010681 | Jan 2008 | WO |
WO 2008011625 | Jan 2008 | WO |
2008053481 | May 2008 | WO |
WO 2008053481 | May 2008 | WO |
2008069566 | Jun 2008 | WO |
WO 2008069566 | Jun 2008 | WO |
2008083209 | Jul 2008 | WO |
2008091602 | Jul 2008 | WO |
WO 2008083209 | Jul 2008 | WO |
WO 2008091602 | Jul 2008 | WO |
2009040548 | Apr 2009 | WO |
WO 2009040548 | Apr 2009 | WO |
2009066763 | May 2009 | WO |
WO 2009066763 | May 2009 | WO |
WO 2009077859 | Jun 2009 | WO |
2009079712 | Jul 2009 | WO |
2009081122 | Jul 2009 | WO |
WO 2009079712 | Jul 2009 | WO |
WO 2009081122 | Jul 2009 | WO |
2009097660 | Aug 2009 | WO |
WO 2009097660 | Aug 2009 | WO |
2009140735 | Nov 2009 | WO |
WO 2009140735 | Nov 2009 | WO |
2010042996 | Apr 2010 | WO |
WO 2010042996 | Apr 2010 | WO |
2010071918 | Jul 2010 | WO |
WO 2010071918 | Jul 2010 | WO |
2010109471 | Sep 2010 | WO |
WO 2010109471 | Sep 2010 | WO |
2011105496 | Sep 2011 | WO |
2011116388 | Sep 2011 | WO |
WO 2011105496 | Sep 2011 | WO |
WO 2011116388 | Sep 2011 | WO |
2012119907 | Sep 2012 | WO |
2012122162 | Sep 2012 | WO |
WO 2012119907 | Sep 2012 | WO |
WO 2012122162 | Sep 2012 | WO |
2013053022 | Apr 2013 | WO |
2013055641 | Apr 2013 | WO |
WO 2013053022 | Apr 2013 | WO |
WO 2013055641 | Apr 2013 | WO |
2014058746 | Apr 2014 | WO |
WO 2014058746 | Apr 2014 | WO |
2015034924 | Mar 2015 | WO |
WO 2015034924 | Mar 2015 | WO |
WO 2016090356 | Jun 2016 | WO |
WO-2016090356 | Jun 2016 | WO |
2016123665 | Aug 2016 | WO |
WO 2016123665 | Aug 2016 | WO |
2016143514 | Sep 2016 | WO |
WO 2016143514 | Sep 2016 | WO |
WO-2017045031 | Mar 2017 | WO |
2017123652 | Jul 2017 | WO |
WO 2017123652 | Jul 2017 | WO |
2018119174 | Jun 2018 | WO |
WO 2018119174 | Jun 2018 | WO |
Entry |
---|
Aichele et al., “Antiviral Cytotoxic T Cell Response Induced by In Vivo Priming With a Free Synthetic Peptide,” J Exp. Med. 171:1815-1820, May 1990. |
Albert et al., “Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs,” Nature 392:86-89, Mar. 1998. |
Albert et al., “Tumor-specific killer cells in paraneoplastic cerebellar degeneration,” Nature Medicine 4(11): 1321-1324, Nov. 1998. |
Anderson, “Cutaneous Microdialysis: Is it Worth the Sweat?” Journal of Investigative Dermatology 126:1207-1209, 2006. |
Athanasopoulos et al., “Gene therapy vectors based on adeno-associated virus: Characterstics and applications to acquired and inherited diseases (Review),” International Journal of Molecular Medicine 6:363-375, 2000. |
Australian Examination Report dated Apr. 11, 2016 for Australian Application No. 2012323782, 3 pages. |
Australian Examination Report dated Jan. 9, 2017 for Australian Application No. 2012323782, 4 pages. |
Australian Examination Report dated Mar. 27, 2013 for Australian Application No. 2009212106, 5 pages. |
Australian Examination Report No. 1 dated Oct. 9, 2020 for Australian Application No. 2016333148, 5 pages. |
Bachmann et al., “Dendiritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes,” Eur. J. Immunol. 26:2595-2600, 1996. |
Boehm et al., “Inkjet printing for pharmaceutical applications,” Materials Today 17(5):247-252, Jun. 2014. |
Camilli et al., “Listeria monocytogenes Mutants Lacking Phosphatidylinositol-specific Phospholipase C are Avirulent,” J. Exp. Med. 173:751-754, Mar. 1991. |
Canadian Examination Report dated Apr. 23, 2015 for Canadian Application No. 2,749,347, 4 pages. |
Canadian Examination Report dated Feb. 17, 2015 for Canadian Application No. 2,745,339, 4 pages. |
Chinese Office Action dated Dec. 28, 2012 for Chinese Application No. 200980104635.3, 6 pages. (w/ English Translation). |
Chinese Office Action dated Feb. 17, 2012 for Chinese Application No. 200980104635.3, 13 pages. (w/ English Translation). |
Chinese Office Action dated Jan. 11, 2021 for Chinese Application No. 201880036675.8, 31 pages. (w/ machine translation). |
Chinese Office Action dated Sep. 24, 2012 for Chinese Application No. 200980104635.3, 9 pages. (w/ English Translation). |
Communication pursuant to Article 94(3) EPC, dated Jan. 19, 2021, for European Application No. 16 746 000.5, 4 pages. |
Cormier et al., “Transdermal delivery of desmopressin using a coated microneedle array patch system,” Journal of Controlled Release 97:503-511, 2004. |
Cox et al., “Adjuvants—a classification and review of their modes of action,” Vaccine 15(3):248-256, 1997. |
Crichton et al., “The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine,” Biomaterials 31:4562-4572, 2010. |
Crichton et al., “The viscoelastic, hyperelastic and scale dependent behaviour of freshly excised individual skin layers,” Biomaterials 32:4670-4681, 2011. |
Desai et al., “Understanding release kinetics of biopolymer drug delivery microcapsules for biomedical applications,” Materials Science and Engineering B 168:127-131, 2010. |
Dreyer, “Microneedles:Microprocessing in Medicine,” ENMA465: Microprocessing May 10, 2004. (23 pages). |
European Search Report dated Jul. 20, 2012 for European Application No. 09833918.7, 9 pages. |
European Search Report dated Nov. 9, 2015 for European Application No. 12840561.0, 11 pages. |
European Search Report dated Sep. 10, 2018, for European Application No. 16746000.5. (3 pages). |
European Search Report dated Sep. 26, 2014 for European Application No. 09707729.1, 9 pages. |
Extended European Search Report dated Feb. 15, 2021 for European Application No. 18 81 6698, 8 pages. |
Extended European Search Report dated Nov. 30, 2020 for European Application No. 18776793.4, 10 pages. |
Feng et al., “Molecular Biomarkers for Cancer Detection in Blood and Bodily Fluids,” Critical Reviews in Clinical Laboratory Sciences 43(5-6):497-560, 2006. |
Fernando et al., “Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8+ T cell responses,” Journal of Controlled Release 237:35-41, 2016. |
Fernando et al., “Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model,” PLOS One 5(4):e10266, Apr. 2010. (11 pages). |
Fernando et al., “Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (NanopatchTM),” Vaccine 36:3779-3788, 2018. |
Gao et al., “Priming of Influenza Virus-Specific Cytotoxic T Lymphocytes Vivo by Short Synthetic Peptides,” The Journal of Immunology 147(10):3268-3273, Nov. 1991. |
Garafalo et al., “Histamine release and therapy of severe dermatographism,” J. Allergy Clin. Immunol. 68(2):103-105, 1981. |
Gardeniers et al., “Silicon Micromachined Hollow Microneedles for Transdermal Liquid Transport,” Journal of Microelectromechanical Systems 12(6):855-862, Dec. 2003. |
Gill et al., “Coated microneedles for transdermal delivery,” Journal of Controlled Release 117:227-237, 2007. |
Gill et al., “Coating Formulations for Microneedles,” Pharmaceutical Research 24(7):1369-1380, Jul. 2007. |
Henry et al., “Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery,” Journal of Pharmaceutical Sciences 87(8):922-925, Aug. 1998. |
Internal Search Report dated Dec. 6, 2016 for International Application No. PCT/AU2016/050867, 12 pages. |
International Preliminary Report on Patentability dated Feb. 4, 2020 for International Application No. PCT/AU2018/050810, 9 pages. |
International Preliminary Report on Patentability dated Jun. 29, 2010 for International Application No. PCT/AU2008/001903, 7 pages. |
International Preliminary Report on Patentability dated Jun. 7, 2006 for International Application No. PCT/GB2005/000336, 9 pages. |
International Preliminary Report on Patentability dated Nov. 14, 2012 for International Application No. PCT/AU2011/000890, 6 pages. |
International Search Report dated Jul. 30, 2018, for International Application No. PCT/AU2018/050298, 6 pages. |
International Search Report dated Sep. 13, 2018, for International Application No. PCT/AU2018/050847, 4 pages. |
International Search Report dated Aug. 1, 2018, for International Application No. PCT/AU2018/050586, 4 pages. |
International Search Report dated Dec. 22, 2016 for International Application No. PCT/AU2016/050907, 5 pages. |
International Search Report dated Feb. 20, 2009, for International Application No. PCT/AU2008/001903, 11 pages. |
International Search Report dated Feb. 20, 2013 for International Application No. PCT/AU2012/001289, 13 pages. |
International Search Report dated Mar. 7, 2016 for International Application No. PCT/AU2016/050056 , 6 pages. |
International Search Report dated May 25, 2020 for International Application No. PCT/AU2020/050296, 6 pages. |
International Search Report dated Nov. 8, 2018, for International Application No. PCT/AU2018/050810, 8 pages. |
International Search Report dated Oct. 25, 2011 for International Application No. PCT/AU2011/000890, 4 pages. |
Ito et al., “Evaluation of self-dissolving needles containing low molecular weight heparin (LMWH) in rats,” International Journal of Pharmaceutics 349:124-129, 2008. |
Ito et al., “Feasibility of microneedles for percutaneous absorption of insulin,” European Journal of Pharmaceutical Sciences 29:82-88, 2006. |
Ito et al., “Self-dissolving microneedles for the percutaneous absorption of EPO in mice,” Journal of Drug Targeting 14(5):255-261, Jun. 2006. |
Jondal et al., “MHC Class I-Restricted CTL Responses to Exogenous Antigens,” Immunity 5:295-302, Oct. 1996. |
Kay et al., “Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics,” Nature Medicine 7(1):33-40, 2001. |
Kendall et al., “The mechanical properties of the skin epidermis in relation to targeted gene and drug delivery,” Biomaterials 28:4968-4977, 2007. |
Kuzu et al., “In vivo priming effect during various stages of ontogeny of an influenza A virus nucleoprotein peptide,” Eur. J. Immunol. 23:1397-1400, 1993. |
Kwon et al., “In Vitro Modeling of Transdermal PTH Delivery by Dissovling Micro-needle Patch,” TheraJect Inc., 2007. (2 pages). |
Kwon et al., “Rapid Intradermal Drug Delivery by a Dissovable Micro-Needle Patch,” Controlled Release Society 32nd Annual Meeting & Exposition Transactions #306, 2005. (2 pages). |
Kwon, “Acne Treatment by a Dissolvable Micro-Needle Patch,” TheraJect Inc., 2006. (2 pages). |
Kwon, “In Vitro Evaluation of Transdermal Drug Delivery by a Micro-needle Patch,” Controlled Release Society 31st Annual Meeting Transactions #115, 2004. (2 pages). |
Lee et al., “Dissolving microneedles for transdermal drug delivery,” Biomaterials 29:2113-2124, 2008. |
Lin et al., “Silicon-Processed Microneedles,” IEEE Journal of Microelectromechanical Systems 8(1):78-84, Mar. 1999. |
Ma et al., “A PZT Insulin Pump Integrated with a Silicon Micro Needle Array for Transdermal Drug Delivery,” IEEE 56th Electronic Components & Technology Conference, Jun. 2, 2006. (5 pages). |
Ma et al., “Coating solid dispersions on microneedles via a molten dip coating method: development and in vitro evaluation for transdermal delivery of a water insoluble drug,” J Pharm Sci 103(11):3621-3630, 2014. (21 pages). |
Matriano et al., “Macroflux R Microprojection Array Patch Technology: A New and Efficient Approach for Intracutaneous Immunization,” Pharmaceutical Research 19(1):63-70, 2002. |
McAllister et al., “Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies,” PNAS 100(24):13755-13760, Nov. 2003. |
Meléndez et al., “Thermal Inkjet Application in the Preparation of Oral Dosage Forms: Dispensing of Prednisolone Solutions and Polymorphic Characterization by Solid-State Spectroscopic Techniques,” Journal of Pharmaceutical Sciences 97(7):2619-2636, Jul. 2008. |
Mengaud et al., “Expression in Escherichia coli and Sequence Analysis of the Listeriolysin O Determinant of Listeria monocytogenes,” Infection and Immunity 56(4):766-772, Apr. 1988. |
Miyano et al., Hydrolytic Microneedles as Transdermal Drug Delivery System, IEEE The 14th International Conference on Solid-State Sensors, Actuators and Microsyystems, Lyon, France, pp. 355-358, Jun. 10-14, 2007. |
Miyano et al., “Sugar Micro Needles as Transdermic Drug Delivery System,” Biomedical Microdevices 7(3):185-188, 2005. |
Moore et al., “Introduction of Soluble Protein into the Class I Pathway of Antigen Processing and Presentation,” Cell 54:777-785, Sep. 1988. |
Mukerjee et al., “Microneedle array for transdermal biological fluid extraction and in situ analysis,” Sensors and Actuators A 114:267-275, 2004. |
Muller et al., “High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses,” Scientific Reports 7:12644, 2017. (10 pages). |
Ng et al., “Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing,” Scientific Reports 6:29368, 2016. (12 pages). |
Oh et al., “Demonstration of Dose-controlled Delivery by Dissolvable Micro-needle Arrays,” 34th Annual Presented at CRS conference, Jun. 2007. (2 pages). |
Oh et al., “Intradermal influenza vaccine delivery using skin-penetrating dissolveable vaccine microneedles,” AAPS Annual Meeting and Exposition, 2006. (1 page). |
Palmer et al., “Streptolysin O: A Proposed Model of Allosteric Interaction between a Pore-Forming Protein and Its Target Lipid Bilayer,” Biochemistry 37:2378-2383, 1998. |
Park et al., “Biodegradable polymer microneedles: Fabrication, mechanics and transdermal drug delivery,” Journal of Controlled Release 104:51-66, 2005. |
Park et al., “Polymer Microneedles for Controlled-Release Drug Delivery,” Pharmaceutical Research 23(5):1008-1019, 2006. |
Park et al., “Towards the silicon nanowire-based sensor for intracellular biochemical detection,” Biosensors and Bioelectronics 22:2065-2070, 2007. |
Portnoy et al., “Capacity of Listeriolysin O, Streptolysin O, and Perfringolysin O to Mediate Growth of Bacillus subtilis within Mammalian Cells,” Infection & Immunity 60(7):2710-2717, Jul. 1992. |
Radulescu et al., “Uniform Paclitaxel-Loaded Biodegradable Microspheres Manufactured by Ink-Jet Technology,” Proc., the Winter Symposium and 11th International Symposium on Recent Advantages in Drug-Delivery Systems, Controlled Release Society, Salt Lake City, Utah, 2003, 5 pages. |
Rossjohn et al., “Structure of a Cholestrol-Binding, Thiol-Activated Cytolysin and a Model of Its Membrane Form,” Cell 89:685-692, May 1997. |
Sandler et al., “Inkjet Printing of Drug Substances and Use of Porous Substrates-Towards Individualized Dosing,” Journal of Pharmaceutical Sciences 100(8):3386-3395, Aug. 2011. |
Schulz et al., “Peptide-induced antiviral protection by cytotoxic T cells,” Proc. Natl. Acad. Sci. USA 88:991-993, Feb. 1991. |
Scoutaris et al., “Current Trends on Medical and Pharmaceutical Applications of Inkjet Printing Technology,” Pharm Res. 33:1799-1816, 2016. |
Scoutaris et al., “ToF-SIMS analysis of chemical heterogenities in inkjet micro-array printed drug/polymer formulations,” J Mater Sci: Mater Med 23:385-391, 2012. |
Silver et al., “Viscoelastic Properties of Young and Old Human Dermis: A Proposed Molecular Mechanism for Elastic Energy Storage in Collagen and Elastin,” Journal of Applied Polymer Science 86:1978-1985, 2002. |
Stoeber et al., “Arrays of Hollow Out-of-Plane Microneedles for Drug Delivery,” Journal of Microelectromechanical Systems 14(3):472-479, Jun. 2005. |
Sullivan et al., “Minimally Invasive Protein Delivery with Rapidly Dissolving Polymer Microneedles,” Adv. Mater. 20:933-938, 2008. |
Tao et al., “A systematic study of dry etch process for profile control of silicon tips,” Microelectronic Engineering 78-79:147-151, 2005. |
Tarcha et al., “The Application of Ink-Jet Technology for the Coating and Loading of Drug-Eluting Stents,” Annals of Biomedical Engineering 35(10):1791-1799, 2007. |
Tsuchiya et al., “Development of Blood Extraction System for Health Monitoring System,” Biomedcal Microdevices 7(4):347-353, 2005. |
Tyagi et al., “Molecular Beacons: Probes that Fluoresce upon Hybridization,” Nature Biotechnology 14:303-308, Mar. 1996. |
Vigna et al., “Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy,” The Journal of Gene Medicine, 2:308-316, 2000. |
Walther et al., “Viral Vectors for Gene Transfer,” Drugs 60(2):249-271, 2000. |
Wang et al., “Label-free hybridization detection of a single nucleotide mismatch by immobilization of molecular beacons on an agarose film,” Nucleic Acids Research 30(12):e61, 2002. (9 pages). |
Widera et al., “Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system,” Vaccine 24:1653-1664, 2006. |
Wu et al., “Production of viral vectors for gene therapy applications,” Current Opinion in Biotechnology 11:205-208, 2000. |
Wu et al., “Solid free-form fabrication of drug delivery devices,” Journal of Controlled Release 40:77-87, 1996. |
Yuan et al., “Measuring microelastic properties of stratum corneum,” Colloids and Surfaces B: Biointerfaces 48:6-12, 2006. |
Zheng et al., “Multiplexed electrical detection of cancer markers with nanowire sensor arrays,” Nature Biotechnology 23(10):1294-1301, Oct. 2005. |
Zhou et al., “Liposome-Mediated Cytoplasmic Delivery of Proteins: An Effective Means of Accessing the MHC Class I-Restricted Antigen Presentation Pathway,” Immunomethods 4:229-235, 1994. |
Chinese Office Action dated Feb. 14, 2022 for Chinese Application No. 201880036675.8, 12 pages. |
Japanese Office Action dated Feb. 8, 2022 for Japanese Application No. 2019-554394, 6 pages. |
Aichele et al., “Antiviral Cytotoxic T Cell Response Induced by In Vivo Priming With a Free Synthetic Peptide,” J Exp. Med. 171:1815-1820, 1990. |
Albert et al., “Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs,” Nature 392:86-89, 1998. |
Albert et al., “Tumor-specific killer cells in paraneoplastic cerebellar degeneration,” Nature Medicine 4(11):1321-1324, 1998. |
Boehm et al., “Inkjet printing for pharmaceutical applications,” Materials Today 17(5):247-252, 2014. |
Camilli et al., “Listeria monocytogenes Mutants Lacking Phosphatidylinositol-specific Phospholipase C are Avirulent,” J. Exp. Med. 173:751-754, 1991. |
Dreyer, “Microneedles:Microprocessing in Medicine,” ENMA465 Project, May 10, 2004. (23 pages). |
European Search Report dated Nov. 10, 2015 for European Application No. 12840561.0, 11 pages. |
Extended European Search Report dated Nov. 30, 2020 for European Application No. 18 77 6793, 10 pages. |
Fernando et al., “Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model,” PLoS One 5(4):e10266, 2010. (11 pages). |
Gao et al., “Priming of Influenza Virus-Specific Cytotoxic T Lymphocytes Vivo by Short Synthetic Peptides,” The Journal of Immunology 147(10):3268-3273, 1991. |
Gardeniers et al., “Silicon Micromachined Hollow Microneedles for Transdermal Liquid Transport,” Journal of Microelectromechanical Systems 12(6):855-862, 2003. |
Gill et al., “Coating Formulations for Microneedles,” Pharmaceutical Research 24(7):1369-1380, 2007. |
Henry et al., “Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery,” Journal of Pharmaceutical Sciences 87(8):922-925, 1998. |
International Search Report dated Dec. 6, 2016 for International Application No. PCT/AU2016/050867, 12 pages. |
International Search Report dated Feb. 20, 2009, for International Application No. PCT/AU2008/001903, 5 pages. |
Ito et al., “Self-dissolving microneedles for the percutaneous absorption of EPO in mice,” Journal of Drug Targeting 14(5):255-261, 2006. |
Jondal et al., “MHC Class I-Restricted CTL Responses to Exogenous Antigens,” Immunity 5:295-302, 1996. |
Kwon, “In Vitro Evaluation of Transdermal Drug Delivery by a Micro-needle Patch,” Controlled Release Society 31st Annual Meeting Transactions #115, 2006. (2 pages). |
Kwon, “In Vitro Modeling of Transdermal PTH Delivery by Dissovling Micro-needle Patch,” TherJect Inc., 2007. (2 pages). |
Kwon, “Rapid Intradermal Drug Delivery by a Dissovable Micro-Needle Patch,” Controlled Release Society 32nd Annual Meeting & Exposition Transactions #306, 2005. (2 pages). |
Lin et al., “Silicon-Processed Microneedles,” IEEE Journal of Microelectromechanical Systems 8(1):78-84, 1999. |
Ma et al., “A PZT Insulin Pump Integrated with a Silicon Micro Needle Array for Transdermal Drug Delivery,” IEEE 56th Electronic Components & Technology Conference, 2006. (5 pages). |
Ma et al., “Coating solid dispersions on microneedles via a molten dip coating method: development and in vitro evaluation for transdermal delivery of a water insoluble drug,” J Pharm Sci 103(11):3621-3630, 2014 (HHS Public Access Author manuscript, available in PMC Nov. 1, 2015)(21 pages). |
McAllister et al., “Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies,” PNAS 100(24):13755-13760, 2003. |
Meléndez et al., “Thermal Inkjet Application in the Preparation of Oral Dosage Forms: Dispensing of Prednisolone Solutions and Polymorphic Characterization by Solid-State Spectroscopic Techniques,” Journal of Pharmaceutical Sciences 97(7):2619-2636, 2008. |
Mengaud et al., “Expression in Escherichia coli and Sequence Analysis of the Listeriolysin O Determinant of Listeria monocytogenes,” Infection and Immunity 56(4):766-772, 1988. |
Moore et al., “Introduction of Soluble Protein into the Class I Pathway of Antigen Processing and Presentation,” Cell 54:777-785, 1988. |
Portnoy et al., “Capacity of Listeriolysin O, Streptolysin O, and Perfringolysin O to Mediate Growth of Bacillus subtilis within Mammalian Cells,” Infection & Immunity 60(7):2710-2717, 1992. |
Rossjohn et al., “Structure of a Cholestrol-Binding, Thiol-Activated Cytolysin and a Model of Its Membrane Form,” Cell 89:685-692, 1997. |
Sandler et al., “Inkjet Printing of Drug Substances and Use of Porous Substrates-Towards Individualized Dosing,” Journal of Pharmaceutical Sciences 100(8):3386-3395, 2011. |
Schulz et al., “Peptide-induced antiviral protection by cytotoxic T cells,” Proc. Natl. Acad. Sci. USA 88:991-993, 1991. |
Stoeber et al., “Arrays of Hollow Out-of-Plane Microneedles for Drug Delivery,” Journal of Microelectromechanical Systems 14(3):472-479, 2005. |
Tyagi et al., “Molecular Beacons: Probes that Fluoresce upon Hybridization,” Nature Biotechnology 14:303-308, 1996. |
Zheng et al., “Multiplexed electrical detection of cancer markers with nanowire sensor Arrays,” Nature Biotechnology 23(10):1294-1301, 2005. |
Extended European Search Report, dated Jan. 1, 2023, for European Application No. 20783280.9-1122, 9 pages. |
Office Action, dated Jan. 17, 2023, for U.S. Appl. No. 17/241,927, Meliga et al., “Microprojection Arrays With Enhanced Skin Penetrating Properties and Methods Thereof,” 47 pages. |
Canadian Office Action, dated Jan. 5, 2023, for Canadian Application No. AU2016050907, 5 pages. |
European Office Action, dated Dec. 13, 2022, for European Application No. 18844031.7-1111, 3 pages. |
Number | Date | Country | |
---|---|---|---|
20210270599 A1 | Sep 2021 | US |
Number | Date | Country | |
---|---|---|---|
62603841 | Jun 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16622092 | US | |
Child | 17323671 | US |